Polyp of colon

Summary

Polyp of colon (MONDO:0021400) is a disease (an umbrella term covering 5 Mondo subtypes) with 4 cohort genes (88 GWAS associations across 17 studies) and 328 clinical trials. Top therapeutic interventions include fospropofol disodium, picosulfuric acid, and prucalopride.

At a glance

• Umbrella term: 5 Mondo subtypes
• Cohort genes: 4
• GWAS associations: 88
• ClinVar variants: 6
• Clinical trials: 328

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	polyp of colon
Mondo ID	MONDO:0021400
MeSH	D003111
ICD-10-CM	K63.5
ICD-11	1408488915
NCIT	C2954
SNOMED CT	68496003
UMLS	C0009376
MedGen	3166
Anatomy (UBERON)	UBERON:0001155
Is cancer (heuristic)	no

Also known as: colon polyp · colonic polyp · polyp of the colon

Data availability: 6 ClinVar variants · 88 GWAS associations (17 studies).

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › colonic disorder › polyp of colon

Related subtypes (12): neuronal intestinal dysplasia, functional diarrhea, megacolon, diverticulitis of colon, cecal disorder, sigmoid disease, functional colonic disease, colitis, colonic neoplasm, colon dysplasia, Chilaiditi syndrome, colonic duplication

Subtypes (5): colon inflammatory polyp, colon juvenile polyp, colon sessile serrated adenoma/polyp, adenomatous colon polyp, colon serrated polyposis

Genetics & variants

GWAS landscape

88 GWAS associations across 17 studies. Top hits map to 29 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs921650	7e-70	GSDMB	?	1.02
rs10505477	4e-34	PCAT1, CASC8, POU5F1B	A	0.07
chr18:46452327	2e-30		A	0.07
rs6983267	6e-30	PCAT1, CASC8, POU5F1B, CCAT2	G	0.07
rs11874392	5e-28	SMAD7	T	0.1
rs4939827	2e-27	SMAD7	T	0.06
rs477859	3e-26	LAMA5	G	0.13
rs1406389	3e-26	GREM1, GREM1-AS1	T	0.12
rs7130173	4e-23	POU2AF2	C	0.1
chr20:60932414	1e-22		T	0.07
rs3087967	1e-22	POU2AF2	T	0.06
rs10891246	5e-22	POU2AF3, COLCA1	A	0.06
rs11066015	1e-21	ACAD10	A	0.24
rs174553	6e-19	FADS1, FADS2	?	0.99
rs16888589	1e-18	LINC00536 - EIF3H	G	0.17
chr15:32999806	1e-18		C	0.06
rs35107139	3e-16	BMP4	C	0.08
rs535025308	6e-16	CHRDL2	G	0.15
rs2293582	1e-15	GREM1, GREM1-AS1	G	0.06
rs12818766	3e-15	CCND2-AS1	G	0.07
chr11:61565908	7e-15		T	0.05
rs7894531	7e-15	RNA5SP299 - LINC02676	G	0.05
chr20:7877416	8e-15		C	0.08
rs72777082	2e-14	RNA5SP299 - LINC02676	A	0.07
rs481326	2e-14	NDUFA5P10 - LINC01768	A	0.05
rs2423151	3e-14	FGFR3P3 - CASC20	A	0.08
chr12:4368607	3e-14		T	0.06
rs174568	7e-14	FADS1, FADS2	C	0.05
rs4976270	1e-13	PITX1-AS1	C	0.05
chr17:811142	2e-13		T	0.04

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90570609	You D	2025	121,940	1,586,499	A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases.
GCST90475319	Verma A	2024	73,737	241,931	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90570621	You D	2025	58,559	1,269,726	A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases.
GCST90570632	You D	2025	58,174	651,471	A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases.
GCST90018827	Sakaue S	2021	22,049	332,368	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90080271	Backman JD	2021	15,366	372,559	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084257	Backman JD	2021	15,366	372,559	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90570616	You D	2025	10,159	772,631	A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases.
GCST90476762	Verma A	2024	8,522	46,983	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479618	Verma A	2024	8,522	46,983	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	3
Tier 3: regulatory	1
Tier 4: intronic/intergenic	45

MAF distribution

Bucket	Variants
common (>=0.05)	47
low_freq (0.01-0.05)	1
rare (<0.01)	0
unknown	2

Functional consequences

Consequence	Count
intron_variant	22
intergenic_variant	10
unknown	9
non_coding_transcript_exon_variant	4
3_prime_UTR_variant	2
stop_gained	1
5_prime_UTR_variant	1
regulatory_region_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs921650	17	39912823	G>A	0.05	intron_variant	GSDMB	7e-70	Tier 4: intronic/intergenic
rs10505477	8	127395198	A>C,G,T	0.5	intron_variant	PCAT1, CASC8, POU5F1B	4e-34	Tier 4: intronic/intergenic
chr18:46452327				0.453			2e-30	Tier 4: intronic/intergenic
rs6983267	8	127401060	G>T	0.434	non_coding_transcript_exon_variant	PCAT1, CASC8, POU5F1B, CCAT2	6e-30	Tier 4: intronic/intergenic
rs11874392	18	48926786	A>G,T	0.05	intron_variant	SMAD7	5e-28	Tier 4: intronic/intergenic
rs4939827	18	48927093	T>A,C	0.479	intron_variant	SMAD7	2e-27	Tier 4: intronic/intergenic
rs477859	20	62362541	A>C,G,T	0.05	stop_gained	LAMA5	3e-26	Tier 1: coding
rs1406389	15	32717277	A>C,G,T	0.05	non_coding_transcript_exon_variant	GREM1, GREM1-AS1	3e-26	Tier 4: intronic/intergenic
rs7130173	11	111283347	A>C,T	0.05	intron_variant	POU2AF2	4e-23	Tier 4: intronic/intergenic
chr20:60932414				0.242			1e-22	Tier 4: intronic/intergenic
rs3087967	11	111286111	T>A,C,G	0.293	3_prime_UTR_variant	POU2AF2	1e-22	Tier 2: splice/UTR
rs10891246	11	111299815	A>G,T	0.296	intron_variant	POU2AF3, COLCA1	5e-22	Tier 4: intronic/intergenic
rs11066015	12	111730205	G>A	0.248	intron_variant	ACAD10	1e-21	Tier 4: intronic/intergenic
rs174553	11	61807686	A>G,T	0.05	intron_variant	FADS1, FADS2	6e-19	Tier 4: intronic/intergenic
rs16888589	8	116623363	A>G	0.05	intergenic_variant	LINC00536 - EIF3H	1e-18	Tier 4: intronic/intergenic
chr15:32999806				0.209			1e-18	Tier 4: intronic/intergenic
rs35107139	14	53952388	A>C,G,T	0.05	5_prime_UTR_variant	BMP4	3e-16	Tier 2: splice/UTR
rs535025308	11	74721143	G>C	0.033	intron_variant	CHRDL2	6e-16	Tier 4: intronic/intergenic
rs2293582	15	32718211	G>A,C,T	0.189	non_coding_transcript_exon_variant	GREM1, GREM1-AS1	1e-15	Tier 4: intronic/intergenic
rs12818766	12	4266925	G>A,T	0.156	intron_variant	CCND2-AS1	3e-15	Tier 4: intronic/intergenic
chr11:61565908				0.345			7e-15	Tier 4: intronic/intergenic
rs7894531	10	8692798	G>A,T	0.288	intergenic_variant	RNA5SP299 - LINC02676	7e-15	Tier 4: intronic/intergenic
chr20:7877416				0.159			8e-15	Tier 4: intronic/intergenic
rs72777082	10	8696322	G>A,C	0.05	intergenic_variant	RNA5SP299 - LINC02676	2e-14	Tier 4: intronic/intergenic
rs481326	1	109822246	A>G	0.369	regulatory_region_variant	NDUFA5P10 - LINC01768	2e-14	Tier 3: regulatory
rs2423151	20	6402880	G>A	0.05	intergenic_variant	FGFR3P3 - CASC20	3e-14	Tier 4: intronic/intergenic
chr12:4368607				0.158			3e-14	Tier 4: intronic/intergenic
rs174568	11	61826344	C>A,T	0.311	intron_variant	FADS1, FADS2	7e-14	Tier 4: intronic/intergenic
rs4976270	5	135131530	C>T	0.446	intron_variant	PITX1-AS1	1e-13	Tier 4: intronic/intergenic
chr17:811142				0.446			2e-13	Tier 4: intronic/intergenic

ClinVar germline variants

6 retrieved; paginated sample, class counts are floors:

3 uncertain significance, 2 conflicting classifications of pathogenicity, 1 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
233781	NM_000535.7(PMS2):c.251-2A>C	PMS2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
90589	NM_000251.3(MSH2):c.1275A>G (p.Glu425=)	MSH2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
127793	NM_000535.7(PMS2):c.620G>A (p.Gly207Glu)	PMS2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
599334	NM_000534.5(PMS1):c.79G>C (p.Glu27Gln)	PMS1	Uncertain significance	criteria provided, multiple submitters, no conflicts
599335	NM_000534.5(PMS1):c.985C>G (p.Leu329Val)	PMS1	Uncertain significance	criteria provided, single submitter
599331	NM_022367.4(SEMA4A):c.427G>A (p.Gly143Ser)	SEMA4A	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 8 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SEMA4A	Orphanet:1872	Cone rod dystrophy
SEMA4A	Orphanet:440437	Familial colorectal cancer Type X
SEMA4A	Orphanet:791	Retinitis pigmentosa
MSH2	Orphanet:144	Lynch syndrome
MSH2	Orphanet:252202	Constitutional mismatch repair deficiency syndrome
PMS1	Orphanet:144	Lynch syndrome
PMS2	Orphanet:144	Lynch syndrome
PMS2	Orphanet:252202	Constitutional mismatch repair deficiency syndrome

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	4

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SEMA4A	HGNC:10729	ENSG00000196189	Q9H3S1	Semaphorin-4A	clinvar
MSH2	HGNC:7325	ENSG00000095002	P43246	DNA mismatch repair protein Msh2	clinvar
PMS1	HGNC:9121	ENSG00000064933	P54277	PMS1 protein homolog 1	clinvar
PMS2	HGNC:9122	ENSG00000122512	P54278	Mismatch repair endonuclease PMS2	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SEMA4A	Semaphorin-4A	Cell surface receptor for PLXNB1, PLXNB2, PLXNB3 and PLXND1 that plays an important role in cell-cell signaling.
MSH2	DNA mismatch repair protein Msh2	Component of the post-replicative DNA mismatch repair system (MMR).
PMS1	PMS1 protein homolog 1	Probably involved in the repair of mismatches in DNA.
PMS2	Mismatch repair endonuclease PMS2	Component of the post-replicative DNA mismatch repair system (MMR).

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 3 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	1	4.3×	0.404
Other/Unknown	3	1.3×	0.404

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SEMA4A	Scaffold/PPI	no		Semap_dom, Plexin_repeat, WD40/YVTN_repeat-like_dom_sf
MSH2	Other/Unknown	no		DNA_mismatch_repair_MutS_C, DNA_mismatch_repair_MutS-lik_N, DNA_mismatch_repair_MutS_core
PMS1	Other/Unknown	no		MutL/Mlh/PMS, HMG_box_dom, DNA_mismatch_S5_2-like
PMS2	Other/Unknown	no		MutL/Mlh/PMS, DNA_mismatch_S5_2-like, Ribsml_uS5_D2-typ_fold_subgr

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
leukocyte	1
monocyte	1
mononuclear cell	1
oocyte	1
secondary oocyte	1
ventricular zone	1
left testis	1
male germ cell	1
sperm	1
male germ line stem cell (sensu Vertebrata) in testis	1
prefrontal cortex	1
thymus	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SEMA4A	219	broad	marker	monocyte, mononuclear cell, leukocyte
MSH2	278	ubiquitous	marker	secondary oocyte, oocyte, ventricular zone
PMS1	286	ubiquitous	marker	sperm, male germ cell, left testis
PMS2	143	ubiquitous	marker	thymus, prefrontal cortex, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MSH2	4,537
PMS2	2,658
PMS1	2,238
SEMA4A	997

Intra-cohort edges

A	B	Sources
MSH2	PMS1	string_interaction
MSH2	PMS2	string_interaction
PMS1	PMS2	string_interaction

Structural data

PDB: 3 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MSH2	P43246	30
PMS2	P54278	9
PMS1	P54277	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
SEMA4A	Q9H3S1	85.05

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 22. Enrichment computed across 4 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	2	543.8×	5e-05	MSH2, PMS2
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)	2	543.8×	5e-05	MSH2, PMS2
TP53 Regulates Transcription of DNA Repair Genes	2	120.8×	7e-04	MSH2, PMS2
Defective Mismatch Repair Associated With MLH1	1	1903.3×	0.002	PMS2
Defective Mismatch Repair Associated With MSH3	1	1903.3×	0.002	MSH2
Defective Mismatch Repair Associated With MSH6	1	1903.3×	0.002	MSH2
Defective Mismatch Repair Associated With PMS2	1	1903.3×	0.002	PMS2
Defective Mismatch Repair Associated With MSH2	1	1268.9×	0.002	MSH2
Mismatch Repair	1	951.7×	0.002	MSH2
Diseases of Mismatch Repair (MMR)	1	951.7×	0.002	MSH2
Other semaphorin interactions	1	200.3×	0.010	SEMA4A
Diseases of DNA repair	1	190.3×	0.010	MSH2
Semaphorin interactions	1	131.3×	0.013	SEMA4A
DNA Repair	1	32.8×	0.047	MSH2
Transcriptional Regulation by TP53	1	20.7×	0.070	MSH2
Axon guidance	1	15.1×	0.088	SEMA4A
Nervous system development	1	14.3×	0.088	SEMA4A
RNA Polymerase II Transcription	1	7.5×	0.156	MSH2
Gene expression (Transcription)	1	6.0×	0.184	MSH2
Generic Transcription Pathway	1	5.0×	0.203	MSH2
Developmental Biology	1	4.8×	0.203	SEMA4A
Disease	1	4.4×	0.212	MSH2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
mismatch repair	3	486.1×	5e-07	MSH2, PMS1, PMS2
somatic recombination of immunoglobulin gene segments	2	2106.5×	5e-06	MSH2, PMS2
positive regulation of isotype switching to IgA isotypes	2	1404.3×	8e-06	MSH2, PMS2
positive regulation of isotype switching to IgG isotypes	2	766.0×	2e-05	MSH2, PMS2
somatic hypermutation of immunoglobulin genes	2	526.6×	4e-05	MSH2, PMS2
somatic recombination of immunoglobulin genes involved in immune response	1	4213.0×	0.002	MSH2
positive regulation of excitatory synapse assembly	1	1404.3×	0.003	SEMA4A
positive regulation of inhibitory synapse assembly	1	1404.3×	0.003	SEMA4A
B cell mediated immunity	1	1053.2×	0.004	MSH2
maintenance of DNA repeat elements	1	842.6×	0.004	MSH2
response to xenobiotic stimulus	2	34.5×	0.004	PMS1, PMS2
mitotic recombination	1	702.2×	0.005	MSH2
regulation of endothelial cell migration	1	526.6×	0.006	SEMA4A
response to UV-B	1	468.1×	0.006	MSH2
DNA damage tolerance	1	421.3×	0.006	MSH2
T-helper 1 cell differentiation	1	383.0×	0.006	SEMA4A
oxidative phosphorylation	1	351.1×	0.006	MSH2
negative regulation of DNA recombination	1	280.9×	0.008	MSH2
mitotic intra-S DNA damage checkpoint signaling	1	234.1×	0.009	MSH2
response to X-ray	1	221.7×	0.009	MSH2
isotype switching	1	210.7×	0.009	MSH2
negative chemotaxis	1	162.0×	0.011	SEMA4A
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	1	123.9×	0.013	MSH2
germ cell development	1	113.9×	0.014	MSH2
determination of adult lifespan	1	108.0×	0.014	MSH2
semaphorin-plexin signaling pathway	1	100.3×	0.015	SEMA4A
neural crest cell migration	1	84.3×	0.017	SEMA4A
B cell differentiation	1	54.7×	0.025	MSH2
double-strand break repair	1	50.8×	0.026	MSH2
negative regulation of angiogenesis	1	42.1×	0.030	SEMA4A

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 4

Druggability breadth: 2 of 4 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SEMA4A	0	0
MSH2	0	0
PMS1	0	0
PMS2	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MSH2	9	Binding:9
PMS2	1	Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	4	SEMA4A, MSH2, PMS1, PMS2

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SEMA4A	0	—
MSH2	9	—
PMS1	0	—
PMS2	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 328.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	302
PHASE4	8
PHASE2	6
PHASE3	4
PHASE2/PHASE3	3
EARLY_PHASE1	3
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07456111	PHASE4	RECRUITING	A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy
NCT02097394	PHASE4	UNKNOWN	The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps
NCT02688699	PHASE4	UNKNOWN	Additive Hemostatic Efficacy of EndoClot After EMR or ESD in the Gastrointestinal Tract
NCT03742232	PHASE4	COMPLETED	Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.
NCT04065451	PHASE4	COMPLETED	Effect of Epinephrine on Post-polypectomy Pain
NCT04709770	PHASE4	UNKNOWN	Low-volume vs High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis
NCT04758156	PHASE4	UNKNOWN	Comparison Between a 1L of Polyethylene Glycol+Ascorbic Acid as a Split Dose Bowel Preparation for Colonoscopy
NCT06339697	PHASE4	COMPLETED	Short-term Effects of Bowel Preparation on Gut Microbiome in Patients Undergoing Endoscopic Colon Polypectomy
NCT00125424	PHASE2/PHASE3	COMPLETED	Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy
NCT00209573	PHASE3	COMPLETED	A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy
NCT00467922	PHASE3	COMPLETED	An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy
NCT01101672	PHASE2/PHASE3	UNKNOWN	Trial for Single Port Versus Conventional Laparoscopic Colectomy
NCT01200303	PHASE2/PHASE3	COMPLETED	Evaluation of Computer-assisted, Non-cathartic CT Colonography
NCT02588248	PHASE3	TERMINATED	L-Menthol Injection as a Novel Technique During Colonoscopy
NCT05726097	PHASE3	COMPLETED	Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
NCT05776381	PHASE2	NOT_YET_RECRUITING	The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp
NCT00018551	PHASE2	COMPLETED	Chemoprevention With Folic Acid
NCT00209534	PHASE2	COMPLETED	A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy
NCT00209599	PHASE2	TERMINATED	A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy
NCT00825292	PHASE2	COMPLETED	Detection and Classification of Colon Polyps
NCT06812403	PHASE2	COMPLETED	Combination COMBO Endoscopy Oropharyngeal Airway With High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients
NCT01901510	PHASE1	COMPLETED	Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep
NCT02156557	PHASE1	COMPLETED	Study of KCC Peptide Application in the Colon
NCT01254435	EARLY_PHASE1	COMPLETED	Positioning During Colonoscopy
NCT01384240	EARLY_PHASE1	TERMINATED	Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia
NCT04858477	EARLY_PHASE1	COMPLETED	Use of the Napoleon to Improve Polyp Measurement in Gastroenterology Fellows
NCT01368289	Not specified	ACTIVE_NOT_RECRUITING	Australian Multicentre Colonic Endoscopic Mucosal Resection Study
NCT02000141	Not specified	ACTIVE_NOT_RECRUITING	The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study
NCT02332785	Not specified	RECRUITING	Prospective Study of Colon Serrated Polyps
NCT03089268	Not specified	ACTIVE_NOT_RECRUITING	Molecular and Histological Characteristics of Serrated Lesions of the Colon
NCT03471793	Not specified	RECRUITING	The Australian Colonic Large Sessile Lesion Endoscopic Resection Study
NCT03865537	Not specified	ACTIVE_NOT_RECRUITING	Cold Snare Endoscopic Mucosal Resection Trial
NCT03891251	Not specified	RECRUITING	Collecting Recorded Videos of Colonoscopy
NCT04117100	Not specified	RECRUITING	Advanced Endo-therapeutic Procedure : Registry-based Observational Study
NCT04220905	Not specified	RECRUITING	Endoscopic Resection of Large Colorectal Polyps: An Observational Cohort Study
NCT05064124	Not specified	RECRUITING	Early DiAgnosis Real-Time Healthcare System for CANcer Trial
NCT05099432	Not specified	RECRUITING	The CARMA Technique Study
NCT05402696	Not specified	RECRUITING	St. Paul’s Advanced Resection Center Cohort for Colorectal Neoplasia (SPARC-C)
NCT05551052	Not specified	ACTIVE_NOT_RECRUITING	CRC Detection Reliable Assessment With Blood
NCT05822895	Not specified	RECRUITING	Review of the Impact of a Computer-aided Real-time Polyp Detection System on Adult Colonoscopy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FOSPROPOFOL DISODIUM	4	3
PICOSULFURIC ACID	4	3
PRUCALOPRIDE	4	2
EPINEPHRINE	4	1
MIDAZOLAM HYDROCHLORIDE	4	1
REMIMAZOLAM BESYLATE	4	1
SIMETHICONE	4	1
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	4	1
PANCREATIN	3	1
PEPPERMINT OIL	3	1
POLYETHYLENE GLYCOL	3	1
POLYETHYLENE GLYCOL 4000	3	1
PROFLAVINE	2	4
RACEPINEPHRINE	2	1